, Tracking Stock Market Picks
Enter Symbol:
Nabi Biopharmaceuticals (NABI) [hlAlert]

down 56.20 %

Nabi Biopharmaceuticals (NABI) rated Buy

Posted on: Monday,  Sep 17, 2007  9:25 AM ET by Dawson James

Dawson James rated Buy Nabi Biopharmaceuticals (NASDAQ: NABI) on 09/17/2007, when the stock price was $4.11. Since
then, Nabi Biopharmaceuticals has lost 56.20% as of 11/08/2012's recent price of $1.80.
If you would have followed this Dawson James's recommendation on NABI, you would have lost 56.2% of your investment in 1879 days.

Nabi Biopharmaceuticals is a biopharmaceutical company focused on the development of products in the areas of nicotine addiction and infectious disease. The Company?s products in development are Nicotine Conjugate Vaccine (NicVAX) and Pentavalent S.aureus Vaccine (PentaStaph). NicVAX is an investigational vaccine. NicVAX is designed to stimulate the immune system to produce highly specific antibodies that bind to nicotine. PentaStaph is an investigational vaccine based on technology that it has licensed on an basis from the National Institutes of Health (NIH).

Dawson James Securities is a full service investment firm with deep expertise in healthcare, biotechnology and technology with a staff of over 50 investment professionals ensures our clients stay ahead of the constant changes in the healthcare capital markets. From our widely-respected institutional research, investment banking and high net worth services to our personalized attention for individual accounts, we provide quality service for our clients. We take pride in the quality and depth of our professionals and encourage you to contact us so we can begin serving your financial needs today.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
9/17/2007 9:25 AM Buy
4.11 9.00
as of 8/27/2015
1 Week   
1 Month   
3 Months   
1 YTD down  -68.02 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy